2 weeks Ago By Defense World Staff
FibroBiologics ( NASDAQ:FBLG – Get Free Report ) ‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports. They presently have a $12.00 price target on the stock.
HC Wainwright’s price target indicates a potential upside of 327.05% from the stock’s previous close. Several other analysts also recently issued reports on FBLG.
Maxim Group started coverage on shares of FibroBiologics in a research note on Tuesday, September 24th. They issued a “buy” rating and a $12.00 price objective for the company.
EF Hutton Acquisition Co. I upgraded shares of FibroBiologics to a “strong-buy” rating in a report on Wednesday, September 4th. View Our Latest Research Report on FibroBiologics FibroBiologics Stock Down 8.
8 % Hedge Funds Weigh In On FibroBiologics Several hedge funds and other institutional investors have recently bought and sold shares of the business. The Manufacturers Life Insurance Company acquired a new stake in FibroBiologics during the third quarter worth about $32,000. Mercer Global Advisors Inc.
ADV acquired a new stake in shares of FibroBiologics during the 2nd quarter valued at about $51,000. Cahaba Wealth Management Inc. purchased a new position in shares of FibroBiologics in the 2nd quarter valued at about $73,000.
Symphony Financial Ltd. Co. acquired a new position in FibroBiologics in the 3rd quarter worth about $76,000.
Finally, Saxon Interests Inc. purchased a new position in FibroBiologics during the second quarter worth approximately $106,000. About FibroBiologics ( Get Free Report ) FibroBiologics, Inc operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S.
and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. Read More Five stocks we like better than FibroBiologics ETF Screener: Uses and Step-by-Step Guide 3 GARP Stocks Offering Strong Growth: Aptiv, Allstate, Barrick How to Invest in Biotech Stocks Mouse Rising: The Iger Investment Pays Off for Disney Investors Top Biotech Stocks: Exploring Innovation Opportunities Can CAVA Stock Be the Next Chipotle? Earnings Can Help Receive News & Ratings for FibroBiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroBiologics and related companies with MarketBeat.com's FREE daily email newsletter .
.
